Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial
Article Abstract:
The drug tamoxifen may reduce the risk of breast cancer in healthy women who have the BRCA2 gene mutation but not in women with the BRCA1 mutation. These two gene mutations have been linked to a higher risk of breast cancer.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
Article Abstract:
A randomized double-blind study of tamoxifen in post-operative therapy among 2644 women who had a malignant breast tumor removed is presented. All of the patients in this study had node-negative cancer and estrogen-receptor-positive tumors. Results of the study indicate that tamoxifen prolongs the disease-free survival of women who have estrogen- receptor-positive breast tumors and has fewer toxic side effects. The effect of tamoxifen may be related more to suppression of existing tumor growth rather than the prevention of new tumor growth. The degree of benefit achieved with tamoxifen is not sufficient to eliminate the need for future trials to evaluate potentially more effective therapies.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1989
User Contributions:
Comment about this article or add new information about this topic:
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer
Article Abstract:
The frequency and types of undetected cancer-predisposing mutations in BRCA1, BRCA2, CHEK2, TP53 and PTEN are determined among patients with breast cancer from high-risk families with negative genetic test results for BRCA1 and BRCA2. The analysis shows that around 12% are expected to carry a large genomic deletion or duplication in one of BRCA1 or BRCA2 genes and approximately 5% are expected to carry a mutation in CHEK2 or TP53.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Homicide and Suicide Rates Associated With Implementation of the Brady Handgun Violence Prevention Act. Criminal records of homicide offenders
- Abstracts: Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
- Abstracts: Incidence of uterine rupture among women with mullerian duct anomalies who attempt vaginal birth after cesarean delivery
- Abstracts: The predictive value of cytologic testing in women with the human immunodeficiency virus who have low-grade squamous cervical lesions: a substudy of a randomized, phase III chemoprevention trial
- Abstracts: Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodological standards